Commercialization of Biomedical Technologies Course
An exciting new course opportunity titled “Commercialization of Biomedical Technologies” (GS 5109) will be offered at the Graduate School of Biomedical Sciences (GSBS) for the upcoming fourth term. The course will be sponsored by BCM Ventures and led by Dr. Michael Dilling and will feature guest lectures from business and venture leaders from BCM, the TMC and beyond. Auditing participants are welcome!
- Course Title: Commercialization of Biomedical Technologies (GS 5109)
- Course Director: Michael Dilling, PhD, CLP, Executive Leader in Commercialization and Technology Management, BCM Ventures
- Registration open!
Don't miss out on this valuable opportunity to expand your knowledge and network within the field of biomedical technologies. We look forward to your active participation.
Startup Incubator
We’ve built a dedicated Ventures Hub and startup incubator, adjacent to the Texas Medical Center’s Innovation zone. Each area is thoughtfully designed to drive collaboration, initiate creativity, and provide easy access to the Ventures team.
Faculty Mentoring
BCM faculty members with experience in commercialization and entrepreneurship will serve as mentors and ambassadors to commercialization with faculty.
- Institutional Advisory Board for Commercialization
- Internal Target Validation Committee
- Internal Device Strategy Committee (coming in 2023)
This comprehensive guide provides detailed information on our commercialization pathways and processes, and the resources and services available to help you. View current guide.
Recent Press Releases
- CORBEVAX®, A COVID19 Vaccine Developed by Bio E- India Based on the RBD Protein Antigen Technology from Texas Children's Hospital Center for Vaccine Development, Receives World Health Organization Emergency Use Listing Approval (January 2024)
- Texas-Developed Patent-Free COVID-19 Vaccine Technology Receives Emergency Use Authorization In Indonesia (September 2022)
- Baylor College of Medicine and Texas Children’s Hospital collaborates with Incepta Vaccines Ltd. to develop a COVID-19 vaccine for Bangladesh (November 2021)
- Deerfield Management and Baylor College of Medicine Announce Blue Square Discoveries to Advance Novel Therapeutic Treatments (May 2021)
